Luminex Corporation

Stock Symbol: 
Case Status: 

Ademi LLP is investigating Luminex (Nasdaq: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin.

Ademi LLP alleges Luminex’s financial outlook is excellent and yet Luminex shareholders will receive only $37 for each share of Luminex they own. The merger agreement unreasonably limits competing bids for Luminex by prohibiting solicitation of further bids, and imposing a termination penalty if Luminex accepts a superior bid. Luminex insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Luminex’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Luminex.